All news

A 7.99% stake in Immunic (IMUX) is held on behalf of underlying clients.

Alpha Vantage · Stock Titan · · AI-summarised by FinFlash

Aberdeen Group plc and abrdn Inc. have reported a beneficial ownership of 7.99%, or 1,090,427 common shares, in Immunic, Inc. (IMUX) as of September 30, 2026. This stake is held on behalf of their underlying clients, with both entities sharing voting and dispositive power over the shares. The filing, a SCHEDULE 13G/A, indicates a passive investment.

Read original source

IMUX company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.